Quadrature Capital Ltd Makes New Investment in argenex SE $ARGX

Quadrature Capital Ltd purchased a new stake in argenex SE (NASDAQ:ARGX) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 20,501 shares of the company’s stock, valued at approximately $11,313,000.

Several other large investors have also made changes to their positions in the business. WPG Advisers LLC bought a new stake in argenex during the 1st quarter valued at approximately $37,000. Brooklyn Investment Group lifted its holdings in shares of argenex by 102.7% during the first quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock worth $44,000 after buying an additional 38 shares during the last quarter. MAI Capital Management boosted its position in shares of argenex by 866.7% in the second quarter. MAI Capital Management now owns 87 shares of the company’s stock valued at $48,000 after acquiring an additional 78 shares during the period. Banque Transatlantique SA acquired a new stake in shares of argenex in the first quarter worth $62,000. Finally, Geneos Wealth Management Inc. raised its stake in argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after purchasing an additional 99 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ARGX. Stifel Nicolaus set a $882.00 price objective on argenex in a report on Thursday, September 18th. Morgan Stanley increased their price objective on shares of argenex from $766.00 to $1,040.00 and gave the company an “overweight” rating in a research note on Wednesday, October 1st. Jefferies Financial Group set a $818.00 target price on shares of argenex and gave the company a “buy” rating in a research report on Tuesday, August 26th. Wedbush upped their target price on shares of argenex from $880.00 to $1,000.00 and gave the company an “outperform” rating in a research note on Friday, November 14th. Finally, Citigroup raised their price target on shares of argenex from $1,041.00 to $1,124.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $903.78.

argenex Price Performance

NASDAQ ARGX opened at $917.63 on Friday. The stock’s 50 day simple moving average is $828.68 and its 200 day simple moving average is $690.94. argenex SE has a one year low of $510.05 and a one year high of $934.13. The firm has a market cap of $56.50 billion, a PE ratio of 39.40, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, October 30th. The company reported $4.40 EPS for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. The company had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.07 billion. argenex had a return on equity of 29.78% and a net margin of 41.58%. As a group, equities analysts expect that argenex SE will post 3.13 earnings per share for the current year.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.